Dihydropyridine CCB — vascular Cav1.2 selectivity. IV continuous infusion form for hypertensive emergencies + intraoperative HTN. Less reflex tachycardia than IR nifedipine.
Half-Life & Elimination Curve (PO: 3h · IV: 3h)
Plasma (PO)t½ Decay (3h)Effect Site (ke0)
0×t½0h100%(10.7 µg/L)
1×t½3h50%(5.34 µg/L)
2×t½6h25%(2.67 µg/L)
3×t½9h12.5%(1.33 µg/L)
4×t½12h6.3%(0.667 µg/L)
5×t½15h3.1%(0.333 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)1.47h
Est. Peak (Cmax)10.7 µg/L
Clearance (CL)139 L/h
97% Washout (5×t½)15h
Dosing Guidelines
Oral (PO): Typical 30 mg (Range: 20–120 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 30% · Volume of Distribution (Vd): 600 L · Absorption (ka): 1.5 h⁻¹ (t½ka ≈ 28m) [PMID 6527979]
Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 600 L [PMID 6527979]